Brokerages Set CeriBell, Inc. (NASDAQ:CBLL) Target Price at $24.67

Shares of CeriBell, Inc. (NASDAQ:CBLL) have earned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $24.6667.

A number of research firms have weighed in on CBLL. Canaccord Genuity Group upped their target price on CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. TD Cowen restated a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. BTIG Research reaffirmed a “buy” rating and set a $30.00 target price on shares of CeriBell in a report on Wednesday, January 28th. Finally, JPMorgan Chase & Co. dropped their price target on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th.

Insider Buying and Selling at CeriBell

In related news, CTO Raymond Woo sold 8,087 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $18.25, for a total transaction of $147,587.75. Following the completion of the sale, the chief technology officer directly owned 166,912 shares in the company, valued at approximately $3,046,144. This trade represents a 4.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Rebecca B. Robertson sold 2,500 shares of CeriBell stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $21.89, for a total transaction of $54,725.00. Following the completion of the transaction, the director owned 19,576 shares in the company, valued at approximately $428,518.64. This trade represents a 11.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 282,968 shares of company stock valued at $6,000,642. Corporate insiders own 20.10% of the company’s stock.

Institutional Investors Weigh In On CeriBell

Several hedge funds have recently modified their holdings of CBLL. TimesSquare Capital Management LLC boosted its position in shares of CeriBell by 48.5% in the 2nd quarter. TimesSquare Capital Management LLC now owns 796,945 shares of the company’s stock valued at $14,927,000 after purchasing an additional 260,116 shares during the period. Geode Capital Management LLC lifted its stake in CeriBell by 55.4% during the second quarter. Geode Capital Management LLC now owns 447,936 shares of the company’s stock valued at $8,391,000 after buying an additional 159,698 shares in the last quarter. Police & Firemen s Retirement System of New Jersey boosted its holdings in shares of CeriBell by 161.0% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock worth $106,000 after buying an additional 3,502 shares during the period. Intech Investment Management LLC purchased a new position in shares of CeriBell in the second quarter worth approximately $266,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of CeriBell by 6,424.8% during the second quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock valued at $7,117,000 after acquiring an additional 374,179 shares during the period.

CeriBell Stock Performance

Shares of CBLL opened at $17.77 on Monday. The firm has a market capitalization of $668.86 million, a PE ratio of -12.09 and a beta of 1.12. The company has a quick ratio of 9.35, a current ratio of 9.73 and a debt-to-equity ratio of 0.13. The firm has a 50-day moving average price of $20.91 and a 200 day moving average price of $16.41. CeriBell has a 52-week low of $10.01 and a 52-week high of $24.33.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The company had revenue of $24.78 million during the quarter, compared to analyst estimates of $23.95 million. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. On average, sell-side analysts anticipate that CeriBell will post -2.46 earnings per share for the current fiscal year.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.